Transcatheter Aortic Valve Replacement (TAVR), also known as, Transcatheter Aortic Valve Implantation (TAVI), is a minimally invasive procedure used to treat severe aortic valve stenosis by implanting a Transcatheter Heart Valve in a patient's diseased aortic valve. The procedure is largely performed transfemorally (through the groin) but can also be performed via alternative pathways including the transapical, transaortic, transcarotid, transsubclavian and transcaval approaches.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Transcatheter Aortic Valve Replacement (TAVR) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Transcatheter Aortic Valve Replacement (TAVR) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to :
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Transcatheter Aortic Valve Replacement (TAVR) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aegis Surgical Limited
- Anteris Technologies Ltd
- AorTx, Inc.
- Arbor Surgical Technologies, Inc.
- Atlas Medical
- Beijing Balance Medical Technology Co Ltd
- Biotronik AG
- Boston Scientific Corp
- Carena Healthcare Ltd
- Chengdu Silara Meditech Inc
- Colibri Heart Valve LLC
- ContiTech (Beijing) Medical Technology Co Ltd
- Daidalos Solutions BV
- Direct Flow Medical Inc (Inactive)
- Dongguan Tiantianxiang Medical Technology Co Ltd
- DSM Dyneema BV
- Dura LLC
- Edwards Lifesciences Corp
- Endoluminal Technology Research LLC
- Florida International University
- Folda LLC
- Foldax Inc
- HLT, Inc.
- JC Medical, Inc.
- JenaValve Technology GmbH
- Jenscare Scientific Co Ltd
- Jinshi Biotechnology (Changshu) Co Ltd
- KOKA Lifesciences Co Ltd
- Laguna Tech USA Inc
- Lepu Medical Technology (Beijing) Co Ltd
- Mayo Clinic
- Medtronic Plc
- Meril Life Sciences Pvt Ltd
- MicroPort CardioFlow Medtech Corp
- Nanjing Saint Medical Technology Co Ltd
- NewMed Medical Co Ltd
- Novogate Medical Ltd.
- NVT GmbH
- P+F Products + Features GmbH
- Peca Labs Inc
- Peijia Medical Ltd
- PolyNova Cardiovascular Inc
- RegenaGraft
- ReValve Med Inc
- SAS Cormove
- Shanghai Healing Medical Instruments Co Ltd
- St. Jude Medical LLC
- Stony Brook University
- Strait Access Technologies (Pty) Ltd
- Suzhou Jiecheng Medical Technology Co Ltd
- Symetis SA
- The University of British Columbia
- Thubrikar Aortic Valve, Inc.
- University College London
- University of California San Francisco
- University of Cambridge
- University of Iowa
- University of Pennsylvania
- Valve Medical Ltd.
- Vascular Concepts Ltd
- Venus Medtech Hangzhou Inc
- Xeltis AG
- Youngheartvalve LLC

